Compare REKR & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REKR | LONA |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5M | 90.4M |
| IPO Year | 2017 | N/A |
| Metric | REKR | LONA |
|---|---|---|
| Price | $0.71 | $8.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 2.0M | 27.7K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,234,000.00 | N/A |
| Revenue This Year | $12.51 | N/A |
| Revenue Next Year | $23.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $4.21 |
| 52 Week High | $3.42 | $14.21 |
| Indicator | REKR | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 39.15 |
| Support Level | $0.70 | $4.31 |
| Resistance Level | $0.92 | $11.44 |
| Average True Range (ATR) | 0.04 | 0.60 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 18.78 | 13.01 |
Rekor Systems Inc is a roadway intelligence company focused on modernizing public safety, urban mobility, and transportation management through solutions. The company delivers services and solutions that collect, connect, and organize mobility data, providing real-time insights to support decision making, enhance situational awareness, enable rapid response, and support predictive analytics. The Company derives its revenues mainly from the licensing and sale of its roadway data and traffic management product and service offerings. These offerings include a mixture of data collection, implementation, engineering, customer support, and maintenance services, as well as software and hardware. The company operates in the United States and other regions.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.